DeepSA, an edit-based generative framework that utilizes deep simulated annealing (SA), was used to develop novel local anesthetics with multiple activities. Researchers from Sichuan University applied DeepSA to generate over 400 analogs of the local anesthetic articaine.

Researchers from Universite de Sherbrooke and University of California San Francisco presented the discovery and preclinical characterization of CCR2-targeting pepducin, PP-101.

Researchers from Qingdao University and affiliated organizations announced data from a preclinical study using the phosphodiesterase 7 (PDE7) inhibitor BRL-50481 to assess the involvement of PDE7 in the stress-induced behavioral and neuron morphological changes.

Mira Pharmaceuticals Inc. has released new preclinical study results for its oral ketamine analogue, Ketamir-2, which is under investigation for potential to treat neurological and neuropsychiatric disorders, including depression, treatment-resistant depression and post-traumatic stress disorder.

Researchers from Shanxi Medical University presented data from a study that aimed to assess the effects of delayed treatment with G protein-coupled receptor 65 (GPR65) agonist BTB-09089 on neurorestoration following ischemic stroke in mice.

Epigenetic silencing could prevent the production of proteins that cause pathologies. CHARM (coupled histone tail for autoinhibition release of methyltransferase), a DNA methylation-based editor, suppressed transcription of prion proteins in the brains of mice.

Many people living with HIV develop mild cognitive impairment and mood problems known as HIV-1-associated neurocognitive disorder (HAND). The activation of the cannabinoid CB1 receptor may be a feasible strategy to treat this disorder, but associated psychoactive side effects restrict their potential.

Lario Therapeutics Ltd. has been awarded a $6 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).